Germany is on track to pass a law on Friday that would legalize the cultivation and consumption of a limited amount of cannabis. It is estimated that 4.5 million Germans currently use the drug, and this law aims to regularize their behavior.
The proposed law, brought by Chancellor Olaf Scholz’s ruling three-party coalition, would allow individuals to cultivate up to three cannabis plants for private consumption and possess up to 25 grams of the drug.
Larger-scale, non-commercial cannabis production would be permitted for members of “cannabis clubs” with a limit of 500 adult members. Only club members would be allowed to consume the cannabis produced by the club.
Health Minister Karl Lauterbach stated that the goal of this law is to crackdown on the black market and drugs-related crime, as well as reduce dealing and the number of cannabis users.
If this law is passed, Germany would become the ninth country to legalize recreational cannabis use. It is already legal in certain areas of the United States and Australia. Additionally, many countries allow its medical use as a painkiller, which Germany plans to regulate in a separate law.
The consumption of cannabis would remain illegal for minors, and there would be strict regulations for young adults. It would also be illegal to consume near schools and playgrounds.
Lauterbach emphasized the need for these restrictions, stating that cannabis is particularly harmful to the still-growing brain. He also made it clear that while consumption is being legalized, it is still a dangerous substance.
The opposition conservatives have spoken out against the new rules, arguing that they are too complicated for authorities to enforce and could potentially lead to greater consumption.
Christian Democrat legislator Tino Sorge accused the coalition of acting like a “state drug dealer” instead of protecting children and young people.
While some experts doubt the new regulations will have a significant impact on dealing, as those who are unwilling to grow their own cannabis or join a club may still prefer to buy the drug on the market.
(Reporting by Thomas Escritt; Editing by Rachel More and Mark Potter)
